C3 Statement Regarding Partnership Between Myonexus and Sarepta Therapeutics

Sarepta Therapeutics recently announced a partnership with Myonexus Therapeutics focused on developing gene therapies for five subtypes of LGMD: 2B, 2C, 2D, and 2L. The agreement states that Sarepta will make an upfront payment of $60 million. If development-related milestones payments are met, Sarepta will make additional payments of up to $45 million over a two-year period. Sarepta also has the option to purchase Myonexus at any time. Additional information can be found here:

https://www.nasdaq.com/press-release/sarepta-therapeutics-announces-partnership-with-myonexus-therapeutics-for-the-advancement-of-20180503-01482

 

This announcement is great news for LGMD2A (also called calpainopathy) patients, as it demonstrates that substantial investment capital is available for promising LGMD therapeutics. Sarepta’s large investment is likely to attract more attention from the biotechnology industry to rare muscular dystrophies. Furthermore, a highly similar treatment approach may be beneficial for LGMD2A patients; therefore, C3 will remain in close contact with Myonexus as their trails progress.

 

C3 recognizes the potential for gene therapy to treat or cure LGMD2A. Click here to support gene therapy research for LGMD2A!